| Date Filed | Type | Description |
| 10/04/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.7% stake in Synlogic, Inc. |
| 10/02/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.5% stake in PMV Pharmaceuticals, Inc. |
| 08/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 5.9% stake in Galecto, Inc. |
| 08/11/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8% stake in Gracell Biotechnologies Inc. |
| 08/03/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 56.7% stake in Xtant Medical Holdings, Inc. |
| 08/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8.3% stake in Galecto, Inc. |
| 07/24/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 9.6% stake in Galecto, Inc. |
| 06/29/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 14.7% stake in Passage BIO, Inc. |
| 06/29/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 15.5% stake in Adicet Bio, Inc. |
| 05/24/2023 |
SC 13D
| ORBIMED ADVISORS LLC reports a 7.7% stake in VectivBio Holding AG |
| 05/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 28.6% stake in Prelude Therapeutics Incorporated |
| 05/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 6.7% stake in SpringWorks Therapeutics, Inc. |
| 05/16/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.6% stake in Fusion Pharmaceuticals Inc. |
| 05/16/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.8% stake in Verona Pharma plc |
| 05/08/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 16.2% stake in Kinnate Biopharma Inc. |
| 05/05/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 67.1% stake in Xtant Medical Holdings, Inc. |
| 05/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.1% stake in Kinnate Biopharma Inc. |
| 04/21/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/31/2023 |
SC 13D
| ORBIMED ADVISORS LLC reports a 11.2% stake in Gracell Biotechnologies Inc. |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 5.4% stake in CalciMedica, Inc. |
| 03/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 0% stake in 89bio, Inc. |
| 03/22/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 18.9% stake in CalciMedica, Inc. |
| 03/14/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 39.6% stake in Theseus Pharmaceuticals, Inc. |
| 02/28/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 10.6% stake in Kinnate Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 8.2% stake in X4 PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in VistaGen Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| ORBIMED ADVISORS LLC reports a 7.9% stake in Verastem, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 10.7% stake in VectivBio Holding AG |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Theravance Biopharma, Inc. |
|